Intuitive Surgical, Inc. ISRG NDXSPXAI
Healthcare · Medical Instruments & Supplies · United States
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
READ MORE ›$424.64
-23.12% 1Y
Market & Price
Market Cap
$150.39B
Current Price
$424.64
High / Low (52W)
$592.85 / $418.55
Beta
1.51
Valuation
Stock P/E
51.53
Industry PE
23.65
Forward P/E
36.01
PEG Ratio
2.23
Book Value
$49.31
Price to Book
8.61
P/S
14.21
EV/EBITDA
37.57
Dividend Yield
-
Profitability & Returns
ROCE
15.96%
ROE
17.23%
ROA
10.24%
Profit Margin
28.15%
Op Margin
30.87%
EPS (Latest Qtr)
$2.28
EPS (TTM)
$8.24
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
3.26
Current Ratio
4.61
Debt
$0
Total Assets
$20.46B
Current Assets
$9.78B
Working Capital
$7.77B
Ownership
Promoter Holding
0.55%
Chg in Prom Hold
-
FII / Inst Holding
89.21%
Chg in FII Hold
0.03%
Financial Snapshot
Enterprise Value
$146.00B
Total Revenue (TTM)
$10.58B
EBITDA
$3.89B
Free Cash Flow
$2.25B
Operating Cash Flow
$3.36B
Shares Outstanding
354.16M
Gross Margin
66.29%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
17.39%
Profit 5Y
29.26%
Revenue (YoY)
23.00%
Earnings (YoY)
18.80%
PROS
- Excellent profit margin of 28.2%.
- Compounding revenue at 17.4% over 5 years.
- Profit CAGR of 29.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 51.5.
- Trading 28.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | PFE Pfizer Inc. SPX | 26.18 | 19.98 | $149.21B | 6.57% | 5.95% | 8.31% | -14.80% | -37.20% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 679.60M | 758.80M | 807.80M | 892.00M | 847.50M | 909.30M | 920.90M | 1.05B | 973.70M | 1.10B | 1.13B | 1.28B | 1.10B | 852.10M | 1.08B | 1.33B | 1.29B | 1.46B | 1.40B | 1.55B | 1.49B | 1.52B | 1.56B | 1.70B | 1.76B | 1.74B | 1.89B | 2.01B | - | 2.25B | 2.44B | 2.51B | 2.87B | 2.77B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 795.70M | 822.10M | 842.70M | 961.90M | 940.30M |
| Gross Profit | 395.80M | 458.80M | 405.00M | 470.90M | 487.00M | 527.20M | 469.80M | 530.10M | 568.10M | 634.00M | 593.80M | 632.30M | 642.30M | 735.70M | 669.60M | 759.00M | 785.60M | 896.00M | 738.20M | 502.90M | 724.30M | 895.80M | 902.60M | 1.02B | 971.40M | 1.06B | 1.01B | 1.02B | 1.05B | 1.11B | 1.17B | 1.17B | 1.25B | 1.37B | - | 1.46B | 1.62B | 1.66B | 1.90B | 1.83B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 879.60M | 874.50M | 902.70M | 1.04B | 975.20M |
| Operating Income | 189.90M | - | 179.00M | 245.40M | 256.40M | - | 193.40M | 259.90M | 280.60M | - | 276.70M | 277.40M | 313.30M | - | 252.20M | 359.00M | 365.70M | - | 283.00M | 80.60M | 270.40M | - | 416.80M | 511.20M | 442.60M | - | 408.10M | 397.60M | 398.90M | 387.60M | 463.20M | 465.80M | 469.40M | 567.30M | - | 578.10M | 743.40M | 759.70M | 864.30M | 855.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 727.70M | 890.00M | 919.70M | 1.09B | 1.06B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 668.50M | 832.10M | 855.20M | 955.60M | 940.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.20M | 167.90M | 146.00M | 156.10M | 114.40M |
| Net Income | 167.30M | 190.00M | 136.40M | 184.50M | 211.00M | 204.00M | 180.80M | 223.00M | 298.60M | -31.50M | 287.60M | 255.30M | 292.50M | 292.50M | 306.50M | 318.30M | 396.80M | 357.70M | 313.50M | 68.00M | 313.90M | 365.20M | 426.30M | 517.20M | 380.50M | 380.60M | 365.60M | 307.80M | 324.00M | 355.30M | 420.80M | 415.70M | 544.90M | 526.90M | - | 698.40M | 658.40M | 704.40M | 794.80M | 821.50M |
| Diluted EPS | 4.40 | 4.99 | 1.18 | 1.57 | 1.77 | 1.71 | 1.57 | 1.94 | 2.56 | -0.28 | 2.44 | 2.15 | 2.45 | 2.45 | 2.56 | 2.67 | 3.33 | 2.99 | 2.62 | 0.57 | 2.60 | 3.02 | 1.17 | 1.42 | 1.04 | 1.03 | 1.00 | 0.85 | 0.90 | 1.00 | 1.18 | 1.16 | 1.51 | 1.46 | - | 1.92 | 1.81 | 1.95 | 2.21 | 2.28 |
| R&D Expense | 51.00M | - | 53.20M | 54.70M | 62.60M | - | 73.50M | 84.60M | 83.40M | - | 95.50M | 95.10M | 107.60M | - | 144.00M | 120.80M | 135.90M | - | 147.10M | 143.20M | 155.00M | - | 159.80M | 162.30M | 165.50M | - | 210.50M | 207.30M | 217.10M | 244.90M | 244.40M | 249.40M | 284.50M | 280.10M | 286.00M | 316.20M | 313.30M | 329.40M | - | 361.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 2.71B | 3.14B | 3.72B | 4.48B | 4.36B | 5.71B | 6.22B | 7.12B | 8.35B | 10.06B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.03B | 2.39B | 2.72B | 3.42B |
| Gross Profit | 414.29M | 620.80M | 751.10M | 1.03B | 1.27B | 1.57B | 1.59B | 1.41B | 1.58B | 1.89B | 2.20B | 2.60B | 3.11B | 2.86B | 3.96B | 4.20B | 4.73B | 5.63B | 6.64B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.62B | 2.96B | 3.29B | 3.70B |
| Operating Income | 206.74M | 310.80M | 377.40M | 555.20M | 694.80M | 878.10M | 852.50M | 544.80M | 740.00M | 949.70M | 1.06B | 1.20B | 1.37B | 1.05B | 1.82B | 1.58B | 1.77B | 2.35B | 2.95B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.94B | 2.22B | 2.85B | 3.62B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.61B | 1.96B | 2.67B | 3.31B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 262.40M | 141.60M | 336.30M | 434.80M |
| Net Income | 144.54M | 204.30M | 232.60M | 381.80M | 495.10M | 656.60M | 671.00M | 418.80M | 588.80M | 738.30M | 670.90M | 1.13B | 1.38B | 1.06B | 1.70B | 1.32B | 1.80B | 2.32B | 2.86B |
| Diluted EPS | 3.70 | 5.12 | 5.93 | 9.47 | 12.32 | 15.98 | 16.73 | 11.11 | 5.18 | 6.26 | 5.77 | 9.49 | 3.85 | 2.94 | 4.66 | 3.65 | 5.03 | 6.42 | 7.87 |
| R&D Expense | 48.86M | 79.40M | 95.10M | 116.00M | 140.20M | 170.00M | 167.70M | 178.00M | 197.40M | 239.60M | 328.60M | 418.10M | 557.30M | 595.10M | 671.00M | 879.00M | 998.80M | 1.15B | 1.31B |
Compounded Sales Growth
| 5 Years: | 17.39% |
| 1 Year: | 23.00% |
Compounded Profit Growth
| 5 Years: | 29.26% |
| 1 Year: | 18.80% |
Stock Price Performance
| 1 Year: | -23.12% |
| 6 Months: | -26.64% |
| 3 Months: | -15.66% |
| 1 Month: | -6.43% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.47B | 1.81B | 2.39B | 3.06B | 4.06B | 3.95B | 3.96B | 4.91B | 6.49B | 5.78B | 7.85B | 9.73B | 11.17B | - | 12.97B | 15.44B | 18.74B | 20.46B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.25B | 7.89B | 7.11B | 9.78B |
| Cash & Equivalents | 34.39M | 122.80M | 194.60M | 221.40M | 279.80M | 465.80M | 553.70M | 782.10M | 600.30M | 714.60M | 1.04B | 648.20M | 857.90M | 1.17B | 1.62B | - | 1.58B | 2.75B | 2.03B | 3.37B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 893.20M | 1.22B | 1.49B | 1.84B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 942.10M | 1.13B | 1.23B | 1.53B |
| Total Liabilities | - | - | 207.86M | 272.40M | 353.00M | 417.50M | 479.10M | 448.90M | 580.00M | 587.80M | 709.10M | 996.40M | 1.16B | 1.45B | 1.41B | - | 1.86B | 2.04B | 2.21B | 2.52B |
| Current Liabilities | - | - | 164.52M | 202.80M | 273.80M | 320.60M | 401.60M | 380.90M | 501.20M | 491.90M | 596.50M | 662.80M | 820.60M | 1.03B | 965.20M | - | 1.42B | 1.66B | 1.75B | 2.01B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 87.00M | - | - | - | - |
| Total Equity | 589.71M | 888.70M | 1.27B | 1.54B | 2.04B | 2.65B | 3.58B | 3.50B | 3.38B | 4.32B | 5.78B | 4.78B | 6.68B | 8.26B | 9.73B | - | 11.04B | 13.31B | 16.43B | 17.82B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 350.00M | 352.30M | 356.60M | 355.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 205.69M | 278.20M | 392.20M | 545.80M | 677.60M | 814.20M | 880.00M | 665.10M | 806.20M | 1.09B | 1.14B | 1.17B | 1.60B | 1.48B | - | 1.49B | 1.81B | 2.42B | 3.03B |
| Investing Cash Flow | -236.40M | -304.50M | -299.50M | -494.30M | -479.00M | -845.70M | 259.00M | -153.90M | -849.50M | -1.28B | 378.70M | -1.05B | -1.15B | -940.60M | - | 1.37B | -360.10M | -3.27B | 665.80M |
| Financing Cash Flow | 118.85M | 98.00M | -66.20M | 7.70M | -12.40M | 119.20M | -910.60M | -692.40M | 159.10M | 514.40M | -1.91B | 126.30M | -168.40M | -85.70M | - | -2.57B | -287.60M | 150.90M | -2.36B |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -532.40M | -1.06B | -1.11B | -539.80M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 958.40M | 749.60M | 1.30B | 2.49B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 289.30M | 1.17B | -706.90M | 1.33B |
| Share Buybacks | 0 | 0 | 150.00M | 198.60M | 331.80M | 238.30M | 1.11B | 1.00B | 183.70M | 42.50M | 2.27B | 0 | 269.50M | 134.30M | 0 | 2.61B | 416.30M | 0 | 2.30B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 69.9% | 70.2% | 69.9% | 69.4% | 65.6% | 69.3% | 67.4% | 66.4% | 67.5% | 66.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | 35.1% | 33.9% | 32.2% | 30.7% | 24.1% | 31.9% | 25.3% | 24.8% | 28.1% | 29.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - | 27.3% | 21.4% | 30.3% | 30.8% | 24.3% | 29.9% | 21.3% | 25.2% | 27.8% | 28.4% |
| ROE % | 16.3% | 16.1% | 15.1% | 18.7% | 18.7% | 18.3% | 19.2% | 12.4% | 13.6% | 12.8% | 14.0% | 16.9% | 16.7% | 10.9% | - | 12.0% | 13.5% | 14.1% | 16.0% |
| ROCE % | - | 23.7% | 23.5% | 26.2% | 25.3% | 24.0% | 23.9% | 15.8% | 16.8% | 16.1% | 20.8% | 17.1% | 15.8% | 10.3% | - | 13.7% | 12.8% | 13.8% | 16.0% |
Shareholding Pattern
Insiders
0.55%
Institutions
89.21%
Public Float
89.70%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.49% | 30.08M | $12.77B |
| 2 | Vanguard Capital Management LLC | 6.52% | 23.08M | $9.80B |
| 3 | State Street Corporation | 4.47% | 15.85M | $6.73B |
| 4 | Price (T.Rowe) Associates Inc | 3.54% | 12.52M | $5.32B |
| 5 | Geode Capital Management, LLC | 2.39% | 8.47M | $3.60B |
| 6 | Capital World Investors | 2.27% | 8.05M | $3.42B |
| 7 | Vanguard Portfolio Management LLC | 2.04% | 7.23M | $3.07B |
| 8 | Morgan Stanley | 1.71% | 6.06M | $2.57B |
| 9 | FMR, LLC | 1.55% | 5.48M | $2.33B |
| 10 | JPMORGAN CHASE & CO | 1.30% | 4.59M | $1.95B |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ISRG
No recent headlines available.